Healio

FDA expands Klisyri approval for actinic keratosis treatment on larger face, scalp areas

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded use area of Klisyri to up to 100 cm 2 on the face and scalp for the treatment ...
The American Journal of Managed Care

FDA-Approved Red-Light LED Lamp Released for Patients With Actinic Keratosis

The announcement followed the release of the RhodoLED XL red light-emitting lamp, to be used in combination with aminolevulinic acid hydrochloride topical gel, 10% for actinic keratoses. The ...
Nasdaq

Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp

BUFFALO, N.Y., May 21, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...
clinicaladvisor.com

New option for actinic keratosis

Pharmacology: The mechanism of action by which ingenol mebutate induces cell death in treating actinic keratosis lesions is unknown. Clinical trials: In two double-blind, vehicle-controlled, clinical ...
Business Insider

Almirall receives positive CHMP opinion for Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis

BARCELONA, Spain, May 21, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Medscape

Tirbanibulin 1% Safe, Well-Tolerated in Extensive Actinic Keratosis

Tirbanibulin ointment 1% shows good safety and tolerability in the treatment of actinic keratosis (AK) in fields of up to 100 cm 2 on the face and scalp. The most common local effects of treatment ...
Medscape

FDA Approves Expansion of Treatment Area for Actinic Keratosis Treatment

The US Food and Drug Administration has approved a supplemental new drug application for tirbanibulin topical ointment, allowing the expansion of the surface area treated for actinic keratosis (AK) of ...
WDAF-TV

Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the first ...
WebMD

Auspitz Sign and Psoriasis: What You Need to Know

What Is the Auspitz Sign? Auspitz sign is a distinctive mark seen when a skin plaque has been removed. Plaques (also called scales) are common in plaque psoriasis, but people with Darier′s disease and ...
Morningstar

Sun Pharma Announces FDA Approval of Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis

The BLU-U Model 4170E offers a compact, easy-to-use option with the same BLU-U safety and efficacy healthcare professionals have trusted for years. The new LED BLU-U is approved for the same ...
Business Insider

Almirall receives positive CHMP opinion for Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis

- Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) and it acts through a selective antiproliferative mechanism of action - The ...